Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab, Pyrotinib, Dalpiciclib, and Endocrine Therapy in HR+/HER2+ Breast Cancer
NCT05577442Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of dalpiciclib, pyrotinib in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05577442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577442.